Hollencrest Capital Management’s GSK GSK Stock Holding History

Hollencrest Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.13K	Hold	117	–	–	﹤0.01%	885
2026 Q1	$6.46K	Hold	117	–	–	﹤0.01%	890
2025 Q4	$5.74K	Sell	117 -160	-58%	-$7.46K	﹤0.01%	891
2025 Q3	$12K	Hold	277	–	–	﹤0.01%	775
2025 Q2	$10.6K	Hold	277	–	–	﹤0.01%	759
2025 Q1	$10.7K	Sell	277 -44	-14%	-$1.61K	﹤0.01%	755
2024 Q4	$10.9K	Hold	321	–	–	﹤0.01%	778
2024 Q3	$13.1K	Buy	321 +44	+16%	+$1.8K	﹤0.01%	718
2024 Q2	$10.7K	Hold	277	–	–	﹤0.01%	738
2024 Q1	$11.9K	Hold	277	–	–	﹤0.01%	693
2023 Q4	$10.3K	Hold	277	–	–	﹤0.01%	721
2023 Q3	$10K	Hold	277	–	–	﹤0.01%	725
2023 Q2	$9.87K	Hold	277	–	–	﹤0.01%	757
2023 Q1	$9.86K	Hold	277	–	–	﹤0.01%	748
2022 Q4	$9.73K	Buy	+277	New	+$9.23K	﹤0.01%	729

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hollencrest Capital Management's GSK Position: Q2 2026 in Review

Hollencrest Capital Management held its GSK (GSK) position steady in Q2 2026 at 117 shares worth $6.13K. The position accounts for ﹤0.01% of the portfolio, ranked #885.

Hollencrest Capital Management first reported a position in GSK in Q4 2022 and has held it in 15 quarters since. The position peaked at $13.1K in Q3 2024. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Hollencrest Capital Management held 117 shares of GSK worth $6.13K as of Q2 2026.
Hollencrest Capital Management left its GSK share count unchanged in Q2 2026.
GSK made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #885 holding.
Hollencrest Capital Management first reported a position in GSK in Q4 2022 and has held it in 15 quarters since.
Hollencrest Capital Management's GSK position peaked at $13.1K in Q3 2024.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.